Manuela Mura

List of Publications by Year
in descending order

31	856	840728 11	610883 24
papers	citations	h-index	g-index

33	33	33	1496
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	MTMR4 SNVs modulate ion channel degradation and clinical severity in congenital long QT syndrome: insights in the mechanism of action of protective modifier genes. Cardiovascular Research, 2021, 117, 767-779.	3.8	34
2	NOS1AP polymorphisms reduce NOS1 activity and interact with prolonged repolarization in arrhythmogenesis. Cardiovascular Research, 2021, 117, 472-483.	3.8	22
3	Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection. Stem Cells Translational Medicine, 2021, 10, 636-642.	3.3	40
4	Cockayne syndrome group A and ferrochelatase finely tune ribosomal gene transcription and its response to UV irradiation. Nucleic Acids Research, 2021, 49, 10911-10930.	14.5	7
5	Use of hiPSC-Derived Cardiomyocytes to Rule Out Proarrhythmic Effects of Drugs: The Case of Hydroxychloroquine in COVID-19. Frontiers in Physiology, 2021, 12, 730127.	2.8	4
6	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi006-A from a patient affected by an autosomal recessive form of long QT syndrome type 1. Stem Cell Research, 2020, 42, 101658.	0.7	4
7	Mesenchymal Stromal Cell Secretome for Tissue Repair. , 2020, , 641-666.		2
8	Generation of two human induced pluripotent stem cell (hiPSC) lines from a long QT syndrome South African founder population. Stem Cell Research, 2019, 39, 101510.	0.7	3
9	Tuning Tissue Ingrowth into Proangiogenic Hydrogels via Dual Modality Degradation. ACS Biomaterials Science and Engineering, 2019, 5, 5430-5438.	5.2	5
10	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi005-A from a patient carrying the KCNQ1-R190W mutation. Stem Cell Research, 2019, 37, 101437.	0.7	1
11	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi007-A from a Long QT Syndrome type 1 patient carrier of two common variants in the NOS1AP gene. Stem Cell Research, 2019, 36, 101416.	0.7	2
12	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi004-A from a carrier of the KCNQ1-R594Q mutation. Stem Cell Research, 2019, 37, 101431.	0.7	2
13	Mesenchymal Stromal Cell Secretome for Tissue Repair. , 2019, , 1-26.		1
14	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi002-A from a patient affected by the Jervell and Lange-Nielsen syndrome and carrier of two compound heterozygous mutations on the KCNQ1 gene. Stem Cell Research, 2018, 29, 157-161.	0.7	3
15	Synthetic extracellular matrix mimic hydrogel improves efficacy of mesenchymal stromal cell therapy for ischemic cardiomyopathy. Acta Biomaterialia, 2018, 70, 71-83.	8.3	41
16	Optimized lentiviral transduction of human amniotic mesenchymal stromal cells. Pharmacological Research, 2018, 127, 49-57.	7.1	4
17	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi003-A from a patient affected by an autosomal recessive form of Long QT Syndrome type 1. Stem Cell Research, 2018, 29, 170-173.	0.7	6
18	Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model. European Heart Journal, 2018, 39, 1446-1455.	2.2	100

#	Article	IF	Citations
19	The KCNH2-IVS9-28A/G mutation causes aberrant isoform expression and hERG trafficking defect in cardiomyocytes derived from patients affected by Long QT Syndrome type 2. International Journal of Cardiology, 2017, 240, 367-371.	1.7	28
20	Induced pluripotent stem cell technology: Toward the future of cardiac arrhythmias. International Journal of Cardiology, 2017, 237, 49-52.	1.7	33
21	Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes. Cardiovascular Research, 2017, 113, 531-541.	3.8	110
22	Modeling Heart Failure in Danon Disease Using Patient-Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Cytotherapy, 2016, 18, S12.	0.7	0
23	Human Induced Pluripotent Stem Cells-Derived Cardiomyocytes Carrying CALM1-F142l Mutation Recapitulate LQTS Phenotype in Vitro. Biophysical Journal, 2016, 110, 263a.	0.5	0
24	Optimized Method to Determine Infarct Size and Stem Cell Engraftment in Rodent Hearts Subjected to Ischemia-Reperfusion Injury. Cytotherapy, 2016, 18, S80-S81.	0.7	0
25	Improving the Cardioprotective and Regenerative Properties of Bone Marrow Derived Mesenchymal Stem Cells Through the Overexpression of IGF1 and BMP2. Cytotherapy, 2016, 18, S81.	0.7	0
26	Donor Age Impairs the Capacity of Human Mesenchymal Stromal Cells to Repair Cardiac and Renal Damage. Cytotherapy, 2016, 18, S16.	0.7	0
27	Novel degradable heparin hydrogel improves the engraftment and therapeutic effect of mesenchymal stromal cells in ischemic heart disease. Cytotherapy, 2015, 17, S54.	0.7	0
28	Conditioned Medium From Human Amniotic Mesenchymal Stromal Cells Limits Infarct Size and Enhances Angiogenesis. Stem Cells Translational Medicine, 2015, 4, 448-458.	3.3	94
29	Combination of miRNA499 and miRNA133 Exerts a Synergic Effect on Cardiac Differentiation. Stem Cells, 2015, 33, 1187-1199.	3.2	31
30	Genotype-Phenotype Correlation in Induced Pluripotent Stem Cell (iPSC)Derived Cardiomyocytes Carrying Calmodulin Mutations. Biophysical Journal, 2014, 106, 333a.	0.5	1
31	XPD mutations in trichothiodystrophy hamper collagen VI expression and reveal a role of TFIIH in transcription derepression. Human Molecular Genetics, 2013, 22, 1061-1073.	2.9	277